Promising new combo for rare lymphoma aims to reduce radiation side effects
NCT ID NCT06583837
First seen Mar 10, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tests a new approach for people with early-stage MALT lymphoma, a slow-growing cancer of the lymph nodes. Participants first take a targeted drug called orelabrutinib, and then receive an ultra-low dose of radiation (4Gy) only if needed based on their response. The goal is to control the disease effectively while minimizing long-term side effects. About 50 adults with stage I or II MALT lymphoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL, MARGINAL ZONE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.